The present work provides an overview of patent protection for second medical use of known chemical compounds, in Brazil and other countries, through the approach of the main controversies related to this theme. That issues encompass aspects related to the legality of the protection granted by the patent, the general requirements of patenteability, the ethic and social concepts and the politic and economic factors involved. This work also introduces the diverging views of the two Brazilian government agencies involved in the procedure for granting patent in the pharmaceutical area, INPI and ANVISA.
Source

Parkinson's disease (PD) is a neurodegenerative disorder associated to selective degeneration of dopaminergic neurons caused by an intricate relationship among dopamine metabolism, oxidative stress and α-synuclein fibrillation. Most therapies for PD have focused on dopamine replacement through the use of both monoamine oxidase inhibitors (MAOIs) and dopamine precursor L-dopa. Interestingly, certain MAOIs have a broad spectrum of action including anti-fibrillogenic properties in a-synuclein aggregation. Herein we revisit the chemical properties of MAOIs and their action on important targets associated with PD, notably α-synuclein fibrillation and dopamine metabolism, discussing the strategies associated with the development of multi-target drugs for neurodegenerative diseases.
Source